Medication Safety:
Exploring interventions to support vulnerable patients taking high-alert medications

Angela Yiu

A dissertation by publication submitted in fulfilment of the requirements for the degree of Master of Pharmacy (Research) Graduate School of Health Discipline of Pharmacy University of Technology Sydney 2019
Certificate of original authorship

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and in the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are appropriately acknowledged within the thesis.

I acknowledge that parts of Chapters 1 and 6 received professional copyediting by Laurel Mackinnon (PhD, ELS) and Glenine Hamlyn (B. Arts) in accordance with the university-endorsed national guidelines for editing a research thesis.

This research is supported by the Australian Government Research Training Program.

Signature of student:

Angela Yiu

Date: 30/08/2018

Angela Yiu
Acknowledgements

I would like to express my deep gratitude to my supervisor Associate Professor Beata Bajorek for her expertise, knowledge, patience, support, kindness and guidance throughout this entire degree. She generously gave me her time to review my papers and provided helpful feedback. Thank you for convincing and inspiring me to pursue research at this point in my career.

I would also like to thank my co-supervisors, Kingsley Ng and Dr Vincent Lee for sharing their knowledge, expertise and wisdom into this project and for reminding me to be patient-focused.

In addition, I would like to thank my collaborators such as Dr. Steven Lee and his colleagues for their support during my studies and Dr. Alison Beauchamp for her expertise and advice with the health literacy questionnaire. I am also grateful to Dr. Riana Rahamwati, Terry Royce and Eddy Dharmadji from UTS for helping me with my queries throughout the course.

Finally, I would like to thank my parents, siblings, my darling children, and especially my wonderful partner, for their constant support and encouragement throughout the degree.
Abstract

Ensuring patient safety around high-risk medications such as oral anticoagulants is a global challenge. Several patient-focused interventions have been used to support vulnerable patients such as older persons taking oral anticoagulants. However, limited research has been done to support those with limited health literacy, and those from cultural and linguistic diverse (CALD) backgrounds.

Qualitative and quantitative methods were used to identify the limitations in health literacy, warfarin knowledge gaps, patient’s and carer’s needs and preferences for medicine information about oral anticoagulants.

A double-sided A4 size Warfarin action Plan leaflet was developed, and feedback was obtained from patients and their carers. Several benefits of the action plan were highlighted such as its concise format and understandable content, the use of visuals and how it was interactive. The action plan also addressed the knowledge gaps of patients and carers who had been using warfarin for several years, highlighting the need for regular follow up and education. An unexpected finding was that the WAP had a positive impact on behaviour.

Based on the findings from the feedback on the WAP leaflet and knowledge gaps about NOACs, web-based education materials were assessed to see if they would also have a similar benefit in terms of understandability and actionability. The majority of materials were understandable, however, were not actionable. These findings suggest that there is a need for high quality NOAC medicines information that are actionable.

Overall, this thesis highlights the beneficial role of the written WAP leaflet in supporting older persons taking oral anticoagulants and their carers. The implications of this leaflet is that it could also be used for NOACs and be provided to patients and their carers in a variety of settings such as the hospital and home.
# Table of Contents

**Chapter 1: Introduction and overview of thesis** ................................................................. 1  
1.1. The global challenge: Medication safety ...................................................................... 2  
1.2. Key aspects examined .................................................................................................. 11  
1.3. Research questions ...................................................................................................... 16  
1.4. List of Publications ...................................................................................................... 17  
1.5. Content of Thesis ........................................................................................................ 19  
1.6. Organisation of the thesis ........................................................................................... 23  

**Chapter 2: Patient-focused interventions** ...................................................................... 24  
2.1. Abstract ....................................................................................................................... 25  
2.2. Introduction ................................................................................................................. 27  
2.3. Definitions .................................................................................................................... 29  
2.4. Method ........................................................................................................................ 30  
2.5. Data sources ............................................................................................................... 30  
2.6. Search strategy and search terms .............................................................................. 31  
2.7. Selection criteria ........................................................................................................ 31  
2.8. Data extraction .......................................................................................................... 33  
2.9. Results ....................................................................................................................... 33  
2.10. Comparison of the impact of patient-focused interventions on outcomes ................. 44  
2.11. Discussion ............................................................................................................... 51  
2.12. Conclusion ............................................................................................................... 60  

**Chapter 3: Assessing knowledge and health literacy** ..................................................... 77  
3.1. Introduction ............................................................................................................... 80  
3.2. Method ....................................................................................................................... 82  
3.3. Results ....................................................................................................................... 88  
3.4. Discussion .................................................................................................................. 91  
3.5. Conclusion ............................................................................................................... 97  
3.6. Acknowledgement ..................................................................................................... 98  

**Chapter 4: Warfarin Action Plan (WAP)** ...................................................................... 106  
4.1. Introduction ............................................................................................................... 109  
4.2. Methods ..................................................................................................................... 110  
4.3. Results ....................................................................................................................... 116  
4.4. Discussion .................................................................................................................. 120  
4.5. Conclusion ............................................................................................................... 121  

**Chapter 5: Evaluating NOAC web-based material** ....................................................... 130  
5.1. Introduction ............................................................................................................... 133
List of Tables

Table 1.1 Examples of high-risk or high-alert medications ................................................................. 4
Table 2.1 INR monitoring interventions to support older persons .......................................................... 62
Table 2.2 Patient education interventions to support older persons ....................................................... 68
Table 2.3 Intervention to support those patients with limited literacy and from CALD background ........ 74
Table 3.1 Characteristics of Participants (N=34) .................................................................................. 99
Table 3.2 Patients’ history of warfarin use, medical conditions and medications .................................... 100
Table 3.3 Health Literacy Questionnaire (HLQ) scores for all participants (N=34) ................................. 103
Table 4.1 Participants’ comments about the WAP leaflet ...................................................................... 124
Table 4.2 Illustrative quotes on WAP feedback, focusing on specific information points ..................... 127
Table 4.3 Theme: Reliance on doctors and/or pharmacists for information .......................................... 128
Table 4.4 Theme: Desire for information to ‘normalise’ their life ......................................................... 128
Table 4.5 Theme: Patients and carers acting on new information ......................................................... 129
Table 5.1 Understandability and Actionability scores ........................................................................... 146
# List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Medicines Management Pathway</td>
<td>13</td>
</tr>
<tr>
<td>1.2</td>
<td>Thesis chapters mapped against the educational interventions</td>
<td>15</td>
</tr>
<tr>
<td>1.3</td>
<td>Organisation of this Thesis</td>
<td>23</td>
</tr>
<tr>
<td>2.1</td>
<td>Flow Chart of search strategy and results</td>
<td>76</td>
</tr>
<tr>
<td>3.1</td>
<td>Proportion of participants correctly answering warfarin questions</td>
<td>105</td>
</tr>
<tr>
<td>4.1</td>
<td>Thematic Schema</td>
<td>123</td>
</tr>
<tr>
<td>5.1</td>
<td>Outline of Search strategy</td>
<td>145</td>
</tr>
</tbody>
</table>
List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF</td>
<td>Atrial Fibrillation</td>
</tr>
<tr>
<td>CALD</td>
<td>Cultural and linguistically diverse</td>
</tr>
<tr>
<td>DOACs</td>
<td>Direct-acting oral anticoagulants or Direct oral anticoagulants</td>
</tr>
<tr>
<td>HLQ</td>
<td>Health Literacy Questionnaire</td>
</tr>
<tr>
<td>HMR</td>
<td>Home Medicines Review</td>
</tr>
<tr>
<td>INR</td>
<td>International Normalised Ratio or International normalized ratio</td>
</tr>
<tr>
<td>MMP</td>
<td>Medicines Management Pathway</td>
</tr>
<tr>
<td>NSW</td>
<td>New South Wales</td>
</tr>
<tr>
<td>NOACs</td>
<td>Novel or new oral anticoagulants or Non-Vitamin K antagonists</td>
</tr>
<tr>
<td>NPS</td>
<td>National Prescribing Service</td>
</tr>
<tr>
<td>PEMAT</td>
<td>Patient Education Materials Assessment Tool</td>
</tr>
<tr>
<td>POC</td>
<td>Point of care</td>
</tr>
<tr>
<td>REALM</td>
<td>Rapid Estimate of Adult Literacy in Medicine</td>
</tr>
<tr>
<td>SDM</td>
<td>Shared Decision-Making</td>
</tr>
<tr>
<td>TTR</td>
<td>Time in Therapeutic Range</td>
</tr>
<tr>
<td>WAP</td>
<td>Warfarin action plan</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
List of Definitions

**Medication safety** is defined as freedom from preventable harm with medication use (ISMP Canada, 2007).

**People-centred care** refers to an approach to care that consciously adopts the perspectives of individuals, carers, families and communities as participants in, and beneficiaries of, trusted health systems that are organised around the comprehensive needs of people rather than individual diseases, and respects social preferences. People-centred care also requires that patients receive the education and support they need to make decisions and to participate in their own care. Patient- and person-centred care should encompass both clinical encounters as well as attention to the health of people in their community and their crucial role in shaping policy and health services (World Health Organization Sixty-ninth world health assembly 2016).

**Patient-centred care** (the more widely used term) refers to the provision of care that is respectful of, and responsive to, individual patient preferences, needs and values, and that ensures that the patient’s values guide all clinical decisions (Institute of Medicine 2001)

**Person-centred care** is a model in which healthcare systems are encouraged to partner with patients to co-design and deliver personalised care that provides people with the high-quality care they need and to improve healthcare system efficiency and effectiveness (Santana et al. 2018). Person-centred care is respectful of, and responsive to, the preferences, needs and values of patients and consumers. Key dimensions of person-centred care include respect, emotional
support, physical comfort, information and communication, continuity and transition, care
coordination, involvement of carers and family, and access to care (Australian Commission on
Safety and Quality in Health Care 2011). This is also known as patient-centred care or consumer-
centred care (Australian Commission on Safety and Quality in Health Care (ACSQHC) 2017).

**Consumer-centred care** refers to the provision of care that is easy for patients to obtain when
they need it and ensures that healthcare staff respect and respond to patient choices, needs and
values. Partnerships are formed between patients, their family, carers and healthcare providers
(Australian Commission on Safety and Quality in Health Care 2010).

**Medication incidents** refers to problems that occur in the prescription, dispensing and
administration of medications (Roughead & Semple 2009).

**Adverse drug events** are defined as the proportion of medication incidents that result in patient
harm (Roughead & Semple 2009).

**High-alert medications** are drugs that confer a heightened risk of causing significant patient
harm when they are used inappropriately. Although mistakes may or may not be more common
with these drugs, the consequences of an error are clearly more devastating to patients (Institute for

**Older persons** are defined here as persons aged 65 years and older (Orimo et al. 2006; World
Health Organization 2018a).
**Limited health literacy** is defined by the WHO as “the cognitive and social skills which determine the motivation and ability of individuals to gain access to, understand and use information in ways which promote and maintain good health” (World Health Organization 2018b).

**Culturally and linguistically diverse (CALD)** is defined in Australia as those people born overseas, in countries other than those classified by the Australian Bureau of Statistics as “main English-speaking countries”. The term CALD is also referred to as ‘ethnic minorities’ (Alhomoud et al. 2013; Mohammad, Saini & Chaar 2015), ‘multicultural’, ‘migrants’ and ‘from a non-English speaking background (Smith V and Schaffer E. 2014).